INNOVATE Corp. announced that MediBeacon Inc. has received FDA approval for the next generation MediBeacon TGFR System.
The TGFR System enables kidney function assessment at the point of care by measuring the clearance rate of Lumitrace.
MediBeacon plans to begin initial sales of the TGFR System in the first quarter of 2026.
FDA Approval
MediBeacon's next generation MediBeacon TGFR System has received approval from the U.S. FDA.
Innovative Technology
TGFR System enables non-radioactive kidney function assessment at the point of care.
Market Expansion
MediBeacon expects to scale its technology in inpatient and outpatient settings.
- The approval signifies a major advancement in kidney health assessment technology.
- The reusable TGFR Sensor offers cost benefits and patient comfort compared to the previous version.
The FDA approval of MediBeacon's next generation TGFR System marks a significant milestone in kidney function assessment technology. The market expansion plans demonstrate a promising future for MediBeacon and its innovative products.